These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 8383009)

  • 1. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
    Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
    Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
    Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
    Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
    Hashimoto S; Danks MK; Chatterjee S; Beck WT; Berger NA
    Oncol Res; 1995; 7(1):21-9. PubMed ID: 7549041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
    Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
    Wolverton JS; Danks MK; Granzen B; Beck WT
    Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
    Harker WG; Slade DL; Parr RL; Holguin MH
    Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line.
    Mirski SE; Cole SP
    Cancer Res; 1995 May; 55(10):2129-34. PubMed ID: 7743513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.
    Hinds M; Deisseroth K; Mayes J; Altschuler E; Jansen R; Ledley FD; Zwelling LA
    Cancer Res; 1991 Sep; 51(17):4729-31. PubMed ID: 1651812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R; Beck WT
    Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
    Mo YY; Beck WT
    Oncol Res; 1997; 9(4):193-204. PubMed ID: 9268990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S; Austin CA; Fisher LM
    Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.